Akebia Enters Up to $140MM Term Loan Facility with Symbiotic Capital
Akebia Therapeutics, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, entered into a senior secured term loan facility with Symbiotic Capital. The loan facility consists of an initial tranche of $60 million that was fully funded at closing and the ability to request up...
Read moreDetails

